A novel method for targeted gene therapy in ischemic tissues through viral transfection of an expression cassette containing multiple repetitions of hypoxia response element

Plastic and Reconstructive Surgery

Volumn 123, Issue SUPPL.2S, 2009, Pages

  Cross, Kevin J ^a   Bomsztyk, Elan D ^a   Weinstein, Andrew L ^a   Teo, Esther H ^a   Spector, Jason A ^a   Lyden, David C ^a  

^a Box 20K ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1;

CONFERENCE PAPER; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE CASSETTE; GENE THERAPY; HUMAN; ISCHEMIA; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; ADENO ASSOCIATED VIRUS; ANOXIA; ARTICLE; CELL CULTURE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; PROMOTER REGION; SKIN; VASCULARIZATION;

ANOXIA; CELLS, CULTURED; DEPENDOVIRUS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; ISCHEMIA; MUTAGENESIS, INSERTIONAL; PROMOTER REGIONS, GENETIC; RESPONSE ELEMENTS; SKIN; TRANSFECTION;

EID: 61749092373     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e318191c044     Document Type: Conference Paper

References (26)

1. Anaya-Prado R, Toledo-Pereyra LH, Lentsch AB, Ward PA. Ischemia/reperfusion injury. J Surg Res. 2002;105:248.
2. Khalil AA, Aziz FA, Hall JC. Reperfusion injury. Plast Reconstr Surg. 2006;117:1024.
3. Land WG. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 2005;79:505.
4. Boast K, Binley K, Iqball S, et al. Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum Gene Ther. 1999;10:2197.
5. Hofer T, Desbaillets I, Hopfl G, Gassmann M, Wenger RH. Dissecting hypoxia-dependent and hypoxia-independent steps in the HIF-1alpha activation cascade: Implications for HIF-1alpha gene therapy. FASEB J. 2001;15:2715.
6. Pachori AS, Melo LG, Hart ML, et al. Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. Proc Natl Acad Sci USA. 2004;101:12282.
7. Su H, Arakawa-Hoyt J, Kan YW. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc Natl Acad Sci USA. 2002;99:9480.
8. Buning H, Braun-Falco M, Hallek M. Progress in the use of adeno-associated viral vectors for gene therapy. Cells Tissues Organs 2004;177:139.
9. Braun-Falco M, Doenecke A, Smola H, Hallek M. Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors. Gene Ther. 1999;6:432.
10. Deodato B, Arsic N, Zentilin L, et al. Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Ther. 2002;9:777.
11. Donahue BA, McArthur JG, Spratt SK, et al. Selective uptake and sustained expression of AAV vectors following subcutaneous delivery. J Gene Med. 1999;1:31.
12. Miller DG, Trobridge GD, Petek LM, Jacobs MA, Kaul R, Russell DW. Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol. 2005;79:11434.
13. Zhang X, Godbey WT. Viral vectors for gene delivery in tissue engineering. Adv Drug Deliv Rev. 2006;58:515.
14. Agrawal RS, Muangman S, Layne MD, et al. Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival. Gene Ther. 2004;11:962.
15. Post DE, Van Meir EG. Generation of bidirectional hypoxia/ HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther. 2001;8:1801.
16. Tang Y, Schmitt-Ott K, Qian K, Kagiyama S, Phillips MI. Vigilant vectors: Adeno-associated virus with a biosensor to switch on amplified therapeutic genes in specific tissues in life-threatening diseases. Methods 2002;28:259.
17. Tsui TY, Lau CK, Ma J, et al. Adeno-associated virus-mediated heme oxygenase-1 gene transfer suppresses the progression of micronodular cirrhosis in rats. World J Gastroenterol. 2006; 12:2016.
18. Tsui TY, Wu X, Lau CK, et al. Prevention of chronic deterioration of heart allograft by recombinant adeno-associated virus-mediated heme oxygenase-1 gene transfer. Circulation 2003;107:2623.
19. Wang XH, Wang K, Zhang F, et al. Alleviating ischemia-reperfusion injury in aged rat liver by induction of heme oxygenase-1. Transplant Proc. 2004;36:2917.
20. Tsuji S, Ichioka S, Sekiya N, Nakatsuka T. Analysis of isch-emia-reperfusion injury in a microcirculatory model of pressure ulcers. Wound Repair Regen. 2005;13:209.
21. Peirce SM, Skalak TC, Rodeheaver GT. Ischemia-reperfusion injury in chronic pressure ulcer formation: A skin model in the rat. Wound Repair Regen. 2000;8:68.
22. Sener G, Sert G, Ozer Sehirli A, et al. Pressure ulcer-induced oxidative organ injury is ameliorated by beta-glucan treatment in rats. Int Immunopharmacol. 2006;6:724.
23. Stadler I, Zhang RY, Oskoui P, Whittaker MS, Lanzafame RJ. Development of a simple, noninvasive, clinically relevant model of pressure ulcers in the mouse. J Invest Surg. 2004; 17:221.
24. Korthuis RJ, Durante W. Heme oxygenase-1: A pluripotent sentinel limiting the systemic inflammatory response to extremity ischemia and reperfusion. Crit Care Med. 2005;33: 2701.
25. Maines MD. The heme oxygenase system: Update 2005. An-tioxid Redox Signal. 2005;7:1761.
26. Maines MD, Gibbs PE. 30 some years of heme oxygenase: From a "molecular wrecking ball" to a "mesmerizing" trigger of cellular events. Biochem Biophys Res Commun. 2005; 338:568.